Evidence map›Paper›PMID 31844003›Full record

ArticleAntimicrobial agents and chemotherapy2020

A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.

Shawn M Zimmerman, Audrey-Ann J Lafontaine, Carmen M Herrera, Amanda B Mclean, M Stephen Trent

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Infectious Diseases Impact on Biomedical Devices and Materials.Biomedical materials & devices (New York, N.Y.) · 2022
    Review
  5. Article
  6. Article
  7. A MoSRSC advances · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Polymyxin Delivery Systems: Recent Advances and Challenges.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shawn M ZimmermanDepartment of Infectious Diseases University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Audrey-Ann J LafontaineDepartment of Infectious Diseases University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Carmen M HerreraDepartment of Infectious Diseases University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Amanda B McleanDepartment of Infectious Diseases University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
M Stephen TrentDepartment of Infectious Diseases University of Georgia College of Veterinary Medicine, Athens, Georgia, USA strent@uga.edu.
University of Georgia · USGeorgia College & State University · US

Funding

Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)R01AI129940 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2017 to 2021
$3.3M
The Outer Surface of Vibrio CholeraeR01AI076322 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI TRENT, MICHAEL STEPHEN · 2008 to 2017
$3.2M
Molecular mechanisms required for the maintenance of the gram-negative outer membraneR01AI138576 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2018 to 2022
$2.0M
The Outer Surface of Vibrio choleraeR56AI076322 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI TRENT, MICHAEL STEPHEN · 2013 to 2013
$384k
NIAID NIH HHS R01 AI076322NIAID NIH HHS R01 AI129940NIAID NIH HHS R01 AI138576NIAID NIH HHS R56 AI076322
6 · The paper itself

Abstract

The threat of diminished antibiotic discovery has global health care in crisis. In the United States, it is estimated each year that over 2 million bacterial infections are resistant to first-line antibiotic treatments and cost in excess of 20 billion dollars. Many of these cases result from infection with the ESKAPE pathogens (

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialEnterococcus faeciumEscherichia coliGram-Negative BacteriaGram-Positive BacteriaKlebsiella pneumoniaeMicrobial Sensitivity TestsPolymyxin BPolymyxinsPseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsColistinPolymyxin BPolymyxinsadjuvantadjuvantsantibiotic resistanceantimicrobialantimicrobial agentscolistinlipid Alipopolysaccharidemultidrug-resistant bacteriaouter membranepolymyxin

Identifiers

PMID31844003
PMCPMC7038281
OpenAlexW2994834904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.